Tuesday, 24 April 2018 - 9:52
  • it
  • de
  • en
  • fr

Top stories

News of the week

German biotech Morphosys makes excellent Nasdaq debut

Germany-based biotech Morphosys could not have made any better debut in the Nasdaq. Starting from $25.04, its share price reached $26.16 at the end of its first trading day and closed at $26 last Friday. Morphosys is already traded in…

Teva terminates JV with P&G

Approvals

Procedures / New drug and device authorizations / Recommendations

New FDA approval for US-based biotech Ultragenyx

The Novato, California-based biotech Ultragenyx yesterday announced, before Wall Street opened, that its investigational therapy Crysvita (burosumab) has obtained the FDA approval for the treatment of X–Linked Hypophosphatemia (XLH), a rare condition. XLH is a serious disease affecting bones, which…

Companies

Healthcare market news

German biotech Morphosys makes excellent Nasdaq debut

Germany-based biotech Morphosys could not have made any better debut in the Nasdaq. Starting from $25.04, its share price reached $26.16 at the end of its first trading day and closed at $26 last Friday. Morphosys is already traded in…

Chemistry

Market and Technology

Towards industrialization of enzyme digestion of PET

John McGeehan, researcher at the University of Portsmouth, and his team have published an article on Proceedings of the National Academy of Sciences about PETase enzyme engineering. PETase is an enzyme that catalyzes the conversion of polyethylene terephthalate (PET)–contained in…

M&A

Mergers & Acquisitions

Fresenius abandons $4.3bn acquisition of Akorn

Fresenius has announced today what everyone dreaded. The Bad Homburg (Frankfurt)-based group has informed in a press release it will terminate the program to acquire the US-based Akorn. Fresenius has stated that there are no guarantees for an acquisition, since…

Nutraceuticals

Food supplements

Mybiotics licenses to Ferring technology using bacterial flora to treat female diseases

Israel-based Mybiotics Pharma has signed an agreement with Ferring Holding to license the use of its MyCrobe technology, aimed at developing bacteria that benefit women’s health. MyCrobe has developed bacterial fermentation techniques based on the study of interactions between intestinal…

Pathology

Latest developments

New FDA approval for US-based biotech Ultragenyx

The Novato, California-based biotech Ultragenyx yesterday announced, before Wall Street opened, that its investigational therapy Crysvita (burosumab) has obtained the FDA approval for the treatment of X–Linked Hypophosphatemia (XLH), a rare condition. XLH is a serious disease affecting bones, which…

Safety

News on Product Safety

FDA issues warning about Intercept’s Ocaliva after 19 patients died

The FDA has officially warned doctors about the risks from Intercept Pharmaceuticals’ Ocaliva (obeticholic acid), after 19 patients on Intercept’s drug, developed to treat PBC (Primary Biliary Cholangitis) had died. The FDA, anyway, has specified that the deaths have occurred…

Trials

Preclinical Trials / Clinical Trials / Epidemiology

Genetics study on hair color origin and meaning

The scientific journal Nature Genetics has published an article reporting the results of a study performed by researchers Pirro G. Hysi and Ana M. Valdes, from King’s College London, on 300,000 people’s DNA, aimed at determining the genetic origins of…